Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice

F. Krackhardt, V. Kočka, M. Waliszewski, P. Toušek, B. Janek, M. Trenčan, P. Krajči, F. Lozano, KG. Roman, I. Otaegui, BG. Del Blanco, VV. Del Olmo, EF. Nofrerías, L. Wachowiak, TM. Heang, TH. Ahn, MH. Jeong, BC. Jung, KR. Han, C. Piot, L....

. 2020 ; 99 (8) : e19119. [pub] -

Jazyk angličtina Země Spojené státy americké

Typ dokumentu klinické zkoušky, časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc20005551

Stent designs with ultrathin struts may further increase the procedural success of challenging lesion subsets. The objective of this study was to assess the safety and efficacy of ultrathin strut, polymer-free sirolimus eluting stent (PF-SES) implantations in a large scale, unselected patient population.Adult patients underwent percutaneous coronary interventions (PCI) with a thin-strut PF-SES. Data from two all-comers observational studies having the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled. The accumulated target lesion revascularization (TLR) rate at 9-12 months was the primary endpoint. All dual antiplatelet therapy strategies according to the applicable guidelines were permissible.In total, 7243 patients were prospectively enrolled for PCI with PF-SES in stable coronary artery disease or acute coronary syndrome (ACS). Major risk factors in the overall cohort were diabetes (37.3%), ST elevation myocardial infarction (18.1%) and non-ST myocardial infarction (24.6%). The follow-up rate was 88.6% in the overall population. The TLR rate in the overall cohort was 2.2% whereas definite/probable stent thrombosis (ST) occurred in 0.7%. In patients with in-stent restenosis lesions, the major adverse cardiac events rate was 6.4% whereas the corresponding rate for isolated left main coronary artery (LMCA) disease was highest with 6.7% followed by patients with culprit lesions in vein bypasses (VB, 7.1%). The mortality rate in patients treated in VB lesions was highest with 5.4%, followed by the isolated LMCA subgroup (3.4%) and ACS (2.6%).PCI with PF-SES in an unselected patient population, is associated with low clinical event and ST rates. Furthermore, PF-SES angioplasty in niche indications demonstrated favorable safety and efficacy outcomes with high procedural success rates.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20005551
003      
CZ-PrNML
005      
20200518131935.0
007      
ta
008      
200511s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1097/MD.0000000000019119 $2 doi
035    __
$a (PubMed)32080086
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Krackhardt, Florian $u Department of Internal Medicine and Cardiology, Charite[Combining Acute Accent] - Universita[Combining Diaeresis]tsmedizin Berlin, Campus Virchow Klinikum, Berlin.
245    10
$a Unrestricted use of polymer-free sirolimus eluting stents in routine clinical practice / $c F. Krackhardt, V. Kočka, M. Waliszewski, P. Toušek, B. Janek, M. Trenčan, P. Krajči, F. Lozano, KG. Roman, I. Otaegui, BG. Del Blanco, VV. Del Olmo, EF. Nofrerías, L. Wachowiak, TM. Heang, TH. Ahn, MH. Jeong, BC. Jung, KR. Han, C. Piot, L. Sebagh, J. Rischner, M. Pansieri, M. Leschke,
520    9_
$a Stent designs with ultrathin struts may further increase the procedural success of challenging lesion subsets. The objective of this study was to assess the safety and efficacy of ultrathin strut, polymer-free sirolimus eluting stent (PF-SES) implantations in a large scale, unselected patient population.Adult patients underwent percutaneous coronary interventions (PCI) with a thin-strut PF-SES. Data from two all-comers observational studies having the same protocol (ClinicalTrials.gov Identifiers: NCT02629575 and NCT02905214) were pooled. The accumulated target lesion revascularization (TLR) rate at 9-12 months was the primary endpoint. All dual antiplatelet therapy strategies according to the applicable guidelines were permissible.In total, 7243 patients were prospectively enrolled for PCI with PF-SES in stable coronary artery disease or acute coronary syndrome (ACS). Major risk factors in the overall cohort were diabetes (37.3%), ST elevation myocardial infarction (18.1%) and non-ST myocardial infarction (24.6%). The follow-up rate was 88.6% in the overall population. The TLR rate in the overall cohort was 2.2% whereas definite/probable stent thrombosis (ST) occurred in 0.7%. In patients with in-stent restenosis lesions, the major adverse cardiac events rate was 6.4% whereas the corresponding rate for isolated left main coronary artery (LMCA) disease was highest with 6.7% followed by patients with culprit lesions in vein bypasses (VB, 7.1%). The mortality rate in patients treated in VB lesions was highest with 5.4%, followed by the isolated LMCA subgroup (3.4%) and ACS (2.6%).PCI with PF-SES in an unselected patient population, is associated with low clinical event and ST rates. Furthermore, PF-SES angioplasty in niche indications demonstrated favorable safety and efficacy outcomes with high procedural success rates.
650    _2
$a vstřebatelné implantáty $x škodlivé účinky $7 D020341
650    _2
$a akutní koronární syndrom $x diagnóza $x mortalita $x chirurgie $7 D054058
650    _2
$a senioři $7 D000368
650    _2
$a antibakteriální látky $x terapeutické užití $7 D000900
650    _2
$a cévy - implantace protéz $x metody $7 D019917
650    _2
$a nemoci koronárních tepen $x diagnóza $x mortalita $x chirurgie $7 D003324
650    _2
$a diabetes mellitus $x epidemiologie $7 D003920
650    _2
$a stenty uvolňující léky $x škodlivé účinky $x trendy $7 D054855
650    _2
$a okluze cévního štěpu $x epidemiologie $7 D006083
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a infarkt myokardu bez ST elevací $x komplikace $x epidemiologie $7 D000072658
650    _2
$a koronární angioplastika $x přístrojové vybavení $7 D062645
650    _2
$a polymery $7 D011108
650    _2
$a lékařská praxe - způsoby provádění $x normy $7 D010818
650    _2
$a prospektivní studie $7 D011446
650    _2
$a protézy - design $7 D011474
650    _2
$a rizikové faktory $7 D012307
650    _2
$a infarkt myokardu s elevacemi ST úseků $x komplikace $x epidemiologie $7 D000072657
650    _2
$a sirolimus $x terapeutické užití $7 D020123
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Kočka, Viktor $u University Hospital Královské Vinohrady Prague, Czech Republic.
700    1_
$a Waliszewski, Matthias $u Department of Internal Medicine and Cardiology, Charite[Combining Acute Accent] - Universita[Combining Diaeresis]tsmedizin Berlin, Campus Virchow Klinikum, Berlin. Medical Scientific Affairs, B.Braun Melsungen AG, Berlin, Germany.
700    1_
$a Toušek, Petr $u University Hospital Královské Vinohrady Prague, Czech Republic.
700    1_
$a Janek, Bronislav $u IKEM Prague, Czech Republic.
700    1_
$a Trenčan, Milan $u SÚSCCH, a.s. Banská Bystrica, Slovak Republic.
700    1_
$a Krajči, Peter $u SÚSCCH, a.s. Banská Bystrica, Slovak Republic.
700    1_
$a Lozano, Fernando $u Hospital General Universitario de Ciudad Real, Ciudad Real.
700    1_
$a Roman, Koldobika Garcia-San $u Hospital Universitario de Cruces, Bilbao.
700    1_
$a Otaegui, Imanol $u Hospital Universitari Vall d'Hebron.
700    1_
$a Del Blanco, Bruno Garcia $u Hospital Universitari Vall d'Hebron.
700    1_
$a Del Olmo, Victoria Vilalta $u Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
700    1_
$a Nofrerías, Eduard Fernandez $u Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
700    1_
$a Wachowiak, Lucie $u Medical Scientific Affairs, B.Braun France, Saint Cloud, France.
700    1_
$a Heang, Tay Mok $u Pantai Ayer Keroh Hospital, Malaysia.
700    1_
$a Ahn, Tae Hoon $u Gachon University Gil Medical Center, Incheon.
700    1_
$a Jeong, Myung Ho $u Chonnam National University, Gwangju.
700    1_
$a Jung, Byung-Chun $u Daegu Fatima Hospital.
700    1_
$a Han, Kyu-Rock $u Kangdong Sacred Heart Hospital, South Korea.
700    1_
$a Piot, Christophe $u Clinique du Millénaire, Montpellier.
700    1_
$a Sebagh, Laurent $u Clinique Turin Paris.
700    1_
$a Rischner, Jérôme $u Hôpital Albert Schweitzer Colmar.
700    1_
$a Pansieri, Michel $u Centre Hospitalier d'Avignon, Avignon, France.
700    1_
$a Leschke, Matthias $u Städtische Kliniken Esslingen, Esslingen, Germany.
773    0_
$w MED00012436 $t Medicine $x 1536-5964 $g Roč. 99, č. 8 (2020), s. e19119
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32080086 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20200511 $b ABA008
991    __
$a 20200518131934 $b ABA008
999    __
$a ok $b bmc $g 1524409 $s 1095607
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 99 $c 8 $d e19119 $e - $i 1536-5964 $m Medicine $n Medicine $x MED00012436
LZP    __
$a Pubmed-20200511

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace